# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
InterCure Ltd. has shown resilience in its H1 2024 performance despite facing significant challenges according to research by Z...
Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war i...
Some European cannabis companies are already planning initial public offerings (IPOs) on the Nasdaq, encouraged by the prospect...
The potential rescheduling of cannabis in the U.S.
"Explore InterCure's FY2023 financial results revealing robust revenue growth and operational resilience amidst challen...
Discover how InterCure thrives in 2023 with $95.4M revenue, despite challenges, and plans for global expansion into the U.S. an...